Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
ACELRX PHARMA RG (NQ: ACRX)
4.050 USD  +0.050 (+1.25%)
Official Closing Price  /  Updated: 8:00 PM EDT, Jun 21, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 698,260
Open 4.000
Bid (Size) 4.000 (2300)
Ask (Size) 4.150 (500)
Prev. Close 4.000
Today's Range 3.950 - 4.200
52wk Range 1.650 - 5.750
Shares Outstanding 51,320,598
Dividend Yield N/A
Performance
YTD
+97.56%
+97.56%
1 Month
+39.66%
+39.66%
3 Month
+100.00%
+100.00%
6 Month
+92.86%
+92.86%
1 Year
+62.00%
+62.00%
Top News
More News
Detailed Research: Economic Perspectives on Southern, AcelRx Pharmaceuticals, International Flavors & Fragrances, Pandora Media, Express Scripts Holding, and United Continental — What Drives Growth in
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Southern Company (NYSE:SO),... Read More
from GlobeNewswire News Releases
AcelRx announces FDA acceptance of NDA for DSUVIA
DSUVIA PDUFA date set for November 3, 2018 Read More
from PR Newswire
More News
Read More
Three Arch's shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and Industry Ventures
from PR Newswire
AcelRx Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
from PR Newswire
AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results
from PR Newswire
AcelRx resubmits New Drug Application for DSUVIA™
from PR Newswire
AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems
from PR Newswire
Analyst: AcelRx Will Address FDA Concerns, Secure Approval This Year
category Market News , ACRX , Price Target , and 8 more.
from Benzinga
AcelRx receives positive CHMP opinion for DZUVEO™ for management of acute moderate to severe pain in medically monitored settings
from PR Newswire
Morning Call For Tuesday, June 12
category Stocks / Equities , Bonds , Commodities , and 1 more.
from Blogs - TalkMarkets
BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.23
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.